Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 25
- Registration Number
- NCT02694263
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02305901
- Locations
- 🇩🇪
1307.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128321
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 107
- Registration Number
- NCT02040246
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT01797198
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom
Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT01720290
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 159
- Registration Number
- NCT01720303
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5570
- Registration Number
- NCT01709305
Efficacy of Repaglinide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT01698931
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Padova, Italy
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01605773
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.